Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03805581 · ClinicalTrials.gov registry record · Phase 2
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
A Phase 2 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03805581: Completed Phase 2 study, sponsored by New York Medical College.
NCT03805581 is a Phase 2 study that has completed, run by New York Medical College. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03805581, a Phase 2 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).
Primary Outcome
All patients will be monitored for allergic reaction probably or definitely related to defibrotide administration.
Interventions
- DRUG Defibrotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 2 |
What the finished NCT03805581 record still lists
NCT03805581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Defibrotide is the first listed.
NCT03805581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03805581 about?
NCT03805581 is a clinical study titled "Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome". This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).
What is the current status of trial NCT03805581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-01-12. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT03805581?
The interventions under investigation include: Defibrotide (DRUG).
Who is sponsoring clinical trial NCT03805581?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03805581's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI